XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $74.00 price target on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 191.80% from the stock's current price.
XOMA Trading Down 1.1 %
Shares of XOMA stock traded down $0.28 on Thursday, hitting $25.36. The stock had a trading volume of 6,778 shares, compared to its average volume of 20,852. XOMA has a twelve month low of $13.48 and a twelve month high of $27.00. The firm has a market cap of $295.19 million, a P/E ratio of -6.62 and a beta of 0.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. The company has a fifty day moving average price of $24.80 and a two-hundred day moving average price of $20.34.
XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. As a group, analysts forecast that XOMA will post -1.73 earnings per share for the current fiscal year.
Institutional Investors Weigh In On XOMA
An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC lifted its holdings in XOMA Co. (NASDAQ:XOMA - Free Report) by 25.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 436,602 shares of the biotechnology company's stock after purchasing an additional 87,203 shares during the quarter. XOMA accounts for approximately 2.0% of Stonepine Capital Management LLC's investment portfolio, making the stock its 12th biggest holding. Stonepine Capital Management LLC owned 3.80% of XOMA worth $6,152,000 at the end of the most recent quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Further Reading
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
